Switch to:
Also traded in: Germany
» Details

Insider Trades

Latest Guru Trades with ROSG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research  
Compare:NAS:IDXG, NAS:CBMX, OTCPK:BTHCF, OTCPK:BZYR, NAS:BASI, NAS:MGEN, NAS:HTGM, NAS:GENE, OTCPK:MTST, OTCPK:DIGP, NAS:CAPN, OTCPK:LEDIF, NAS:BIOP, OTCPK:MDIT, NAS:ATOS, OTCPK:MYAN, OTCPK:BMKDF, NAS:TBIO, OTCPK:CRRVF, OTCPK:ABMC » details
Traded in other countries:RQ1.Germany,
Rosetta Genomics Ltd is engaged in the development and commercialization of new diagnostic tests and therapeutics based on a group of genes known as microRNAs.

Rosetta Genomics, Ltd., develops diagnostic tests and therapeutic tools. Its product portfolio comprises of tests such as miRview mets2/mets, miRview squamous, miRview meso and miRview kidney.

Ratios

vs
industry
vs
history
P/B 1.12
ROSG's P/B is ranked higher than
91% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. ROSG: 1.12 )
Ranked among companies with meaningful P/B only.
ROSG' s P/B Range Over the Past 10 Years
Min: 0.48  Med: 2.22 Max: 37.02
Current: 1.12
0.48
37.02
P/S 0.82
ROSG's P/S is ranked higher than
91% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.42 vs. ROSG: 0.82 )
Ranked among companies with meaningful P/S only.
ROSG' s P/S Range Over the Past 10 Years
Min: 0.72  Med: 28.98 Max: 200.29
Current: 0.82
0.72
200.29
Current Ratio 2.70
ROSG's Current Ratio is ranked higher than
52% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. ROSG: 2.70 )
Ranked among companies with meaningful Current Ratio only.
ROSG' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 6.49 Max: 26.26
Current: 2.7
1.14
26.26
Quick Ratio 2.70
ROSG's Quick Ratio is ranked higher than
60% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. ROSG: 2.70 )
Ranked among companies with meaningful Quick Ratio only.
ROSG' s Quick Ratio Range Over the Past 10 Years
Min: 1.14  Med: 6.49 Max: 26.26
Current: 2.7
1.14
26.26
Days Sales Outstanding 106.58
ROSG's Days Sales Outstanding is ranked lower than
81% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.91 vs. ROSG: 106.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
ROSG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.47  Med: 159.8 Max: 885.73
Current: 106.58
27.47
885.73
Days Payable 60.03
ROSG's Days Payable is ranked higher than
55% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.58 vs. ROSG: 60.03 )
Ranked among companies with meaningful Days Payable only.
ROSG' s Days Payable Range Over the Past 10 Years
Min: 60.03  Med: 657.9 Max: 1066.71
Current: 60.03
60.03
1066.71

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -31.10
ROSG's 3-Year Average Share Buyback Ratio is ranked lower than
78% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. ROSG: -31.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ROSG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -236  Med: -68.2 Max: -6.3
Current: -31.1
-236
-6.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.00
ROSG's Price/Net Cash is ranked higher than
72% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.06 vs. ROSG: 6.00 )
Ranked among companies with meaningful Price/Net Cash only.
ROSG' s Price/Net Cash Range Over the Past 10 Years
Min: 1.31  Med: 4.39 Max: 37.67
Current: 6
1.31
37.67
Price/Net Current Asset Value 1.66
ROSG's Price/Net Current Asset Value is ranked higher than
95% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.95 vs. ROSG: 1.66 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ROSG' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.14  Med: 3.08 Max: 9.53
Current: 1.66
1.14
9.53
Price/Tangible Book 1.12
ROSG's Price/Tangible Book is ranked higher than
94% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.33 vs. ROSG: 1.12 )
Ranked among companies with meaningful Price/Tangible Book only.
ROSG' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.88  Med: 2.53 Max: 26.84
Current: 1.12
0.88
26.84
Price/Projected FCF 0.59
ROSG's Price/Projected FCF is ranked higher than
96% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.11 vs. ROSG: 0.59 )
Ranked among companies with meaningful Price/Projected FCF only.
ROSG' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.58  Med: 2.86 Max: 8.69
Current: 0.59
0.58
8.69
Price/Median PS Value 0.03
ROSG's Price/Median PS Value is ranked higher than
99% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. ROSG: 0.03 )
Ranked among companies with meaningful Price/Median PS Value only.
ROSG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.03  Med: 1.11 Max: 6.48
Current: 0.03
0.03
6.48
Earnings Yield (Greenblatt) (%) -345.06
ROSG's Earnings Yield (Greenblatt) (%) is ranked lower than
99% of the 226 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. ROSG: -345.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ROSG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1480.67  Med: 182.9 Max: 691
Current: -345.06
-1480.67
691

More Statistics

Revenue (TTM) (Mil) $10.77
EPS (TTM) $ -0.94
Beta0.76
Short Percentage of Float1.58%
52-Week Range $0.41 - 1.60
Shares Outstanding (Mil)21.96

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 10 13 18 23
EPS ($) -0.66 -0.47 -0.33 -0.18
EPS w/o NRI ($) -0.66 -0.47 -0.33 -0.18
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ROSG

Headlines

Articles On GuruFocus.com
Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $ Dec 08 2008 

More From Other Websites
Rosetta Genomics Reports Preliminary RosettaGX Reveal™ Financial Results for the 2016 Fourth... Feb 08 2017
Rosetta Genomics Announces Key U.S. Patent Allowances for Two RosettaGx RevealTM microRNAs Feb 06 2017
Aegis Restates 'Buy' Rating on Shares of Rosetta Genomics Ltd. (NAS:ROSG) Jan 11 2017
Rosetta Genomics Reports Third Quarter 2016 Financial Results Jan 05 2017
Rosetta Genomics Reports Third Quarter 2016 Financial Results Dec 20 2016
Rosetta Genomics to Present at the 9th Annual LD Micro Main Event Dec 01 2016
Q3 2016 Rosetta Genomics Ltd Earnings Release - After Market Close Nov 30 2016
Rosetta Genomics Announces Pricing of $5 Million Concurrent Registered Direct and Private Placement... Nov 23 2016
Rosetta Genomics Announces Pricing of $5 Million Concurrent Registered Direct and Private Placement... Nov 23 2016
Rosetta Genomics Enters Research Collaboration using microRNA Biomarkers to Predict Response to... Nov 21 2016
Clinical Validation Study for RosettaGX Reveal Published in the Journal of Clinical Pathology Oct 27 2016
Clinical Validation Study for RosettaGX Reveal Published in the Journal of Clinical Pathology Oct 27 2016
RosettaGX Reveal Analytical Validation Study Featured on the Cover of the October Issue of Cancer... Oct 26 2016
RosettaGX Reveal™ Analytical Validation Study Featured on the Cover of the October Issue of Cancer... Oct 24 2016
Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer Oct 20 2016
Rosetta Genomics Fortifies Intellectual Property Portfolio with Two New Patent Allowances for its... Oct 11 2016
Rosetta Genomics Fortifies Intellectual Property Portfolio with Two New Patent Allowances for its... Oct 03 2016
Rosetta Genomics Enters Distribution Agreement for RosettaGX Reveal™ in Israel with Rhenium Sep 29 2016
Edited Transcript of ROSG earnings conference call or presentation 26-Sep-16 8:30pm GMT Sep 27 2016
Rosetta Genomics Reports 2016 Second Quarter Financial Results Sep 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK